Published in N Engl J Med on December 06, 2001
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol (2009) 2.93
Mechanisms of sudden cardiac death. J Clin Invest (2005) 2.90
Drug therapy in chronic heart failure. Postgrad Med J (2003) 2.73
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract (2006) 2.10
Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ (2009) 2.02
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol (2010) 1.93
Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail (2009) 1.78
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging (2008) 1.67
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia (2011) 1.53
Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol (2007) 1.51
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J (2013) 1.47
Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol (2009) 1.46
Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta (2007) 1.45
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol (2006) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol (2008) 1.36
Management of acute decompensated heart failure. CMAJ (2007) 1.33
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (2005) 1.29
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev (2002) 1.16
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag (2010) 1.15
Cardiomyopathy, familial dilated. Orphanet J Rare Dis (2006) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
The prognostic value of non-linear analysis of heart rate variability in patients with congestive heart failure--a pilot study of multiscale entropy. PLoS One (2011) 1.13
Management of chronic heart failure. BMJ (2002) 1.10
Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail (2012) 1.07
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06
Rationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management). BMC Cardiovasc Disord (2007) 1.04
Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther (2008) 1.03
The African-American Heart Failure Trial: background, rationale and significance. J Natl Med Assoc (2002) 1.02
Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacity. J Mol Cell Cardiol (2009) 1.02
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg (2008) 1.00
New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev (2012) 0.98
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96
Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev (2002) 0.96
Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) (2003) 0.96
Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol (2013) 0.95
Evidence-based cardiovascular care in the community: a population-based cross-sectional study. BMC Fam Pract (2004) 0.95
Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One (2010) 0.95
Phosphodiesterase inhibition in heart failure. Heart Fail Rev (2008) 0.95
Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes (2010) 0.95
Comorbid diabetes and end-of-life expenditures among Medicare beneficiaries with heart failure. J Card Fail (2011) 0.95
A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol (2013) 0.94
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail (2012) 0.94
Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev (2013) 0.93
Heart failure in African Americans: unique etiology and pharmacologic treatment responses. J Natl Med Assoc (2003) 0.93
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept (2012) 0.93
Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med (2010) 0.93
Zebrafish heart failure models for the evaluation of chemical probes and drugs. Assay Drug Dev Technol (2013) 0.93
Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag (2009) 0.92
A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.92
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T (2011) 0.92
Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med (2013) 0.92
Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol (2010) 0.90
The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90
Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag (2009) 0.89
MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS One (2013) 0.89
Management of end stage heart failure. Heart (2007) 0.88
Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Ther Adv Chronic Dis (2013) 0.88
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart (2005) 0.88
Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87
Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging (2004) 0.87
Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol (2004) 0.87
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Trends in the medical management of patients with heart failure. J Clin Med Res (2013) 0.86
Linkages between anxiety and outcomes in heart failure. Heart Lung (2011) 0.86
Heart failure in the diabetic population - pathophysiology, diagnosis and management. Arch Med Sci (2014) 0.86
Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail (2016) 0.86
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag (2010) 0.85
Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2016) 0.85
Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep (2012) 0.85
Angiotensin II blockade and renal protection. Curr Pharm Des (2013) 0.85
Congestive heart failure in Indians: how do we improve diagnosis & management? Indian J Med Res (2010) 0.84
Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther (2010) 0.84
Protective role of AT(2) and B(1) receptors in kinin B(2)-receptor-knockout mice with myocardial infarction. Clin Sci (Lond) (2013) 0.84
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med (2001) 8.74
A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med (1995) 7.88
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging (2005) 4.88
The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care (2001) 3.67
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
Health services: an Italian market. Lancet (1996) 3.43
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
The EMIP project. European Myocardial Infarction Project. Eur Heart J (2000) 2.15
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Has clinical pharmacology lost its way? Lancet (1984) 2.02
Clinical pharmacokinetics of diazepam. Clin Pharmacokinet (1978) 1.99
Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. Eur J Clin Pharmacol (1977) 1.94
"Pap" smear and the risk of cervical neoplasia: quantitative estimates from a case-control study. Lancet (1984) 1.87
Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med (1993) 1.81
ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation (1995) 1.75
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation (1993) 1.74
Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation (1997) 1.68
Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J (2001) 1.66
Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. Br Med J (Clin Res Ed) (1987) 1.65
Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol (1982) 1.64
Pharmacokinetics of N-demethyldiazepam in patients suffering from insomnia and treated with nortriptyline. Br J Clin Pharmacol (1975) 1.63
Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med (2005) 1.59
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation (2003) 1.58
Epidemiology of post-infarction risk stratification strategies in a country with a low volume of revascularization procedures. GISSI-Prognosis Investigators. Eur Heart J (1998) 1.56
Risk factors for myocardial infarction in young women. Am J Epidemiol (1987) 1.55
N-desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia (1975) 1.54
Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet (1984) 1.53
Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol (1983) 1.51
Second-generation clinical pharmacology. Lancet (1986) 1.49
The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med (1999) 1.48
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration. Diabet Med (1996) 1.46
Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis (2001) 1.45
Caffeine disposition after oral doses. Clin Pharmacol Ther (1982) 1.39
Benzodiazepines: clinical pharmacology and therapeutic use. Drugs (1980) 1.36
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 1.34
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart (2001) 1.32
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
Information on drug use in pregnancy from the Viewpoint Regional Drug Information Centre. Eur J Clin Pharmacol (1988) 1.28
Internet for clinical trials: past, present, and future. Control Clin Trials (1999) 1.21
Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med (1987) 1.20
Risk factors for endometrial cancer at different ages. J Natl Cancer Inst (1984) 1.18
Tar yield of cigarettes and risk of acute myocardial infarction. GISSI-EFRIM Investigators. BMJ (1993) 1.17
The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes. The QuED Study Group--quality of care and outcomes in type 2 diabetes. Diabetes Care (2001) 1.17
Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol (1989) 1.16
Diazepam elimination in premature and full term infants, and children. J Perinat Med (1973) 1.15
Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol (1990) 1.11
Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. J Neurol Neurosurg Psychiatry (1998) 1.09
Assessment of nausea. Eur J Clin Pharmacol (1990) 1.08
Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet (1982) 1.07
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail (2007) 1.07
Adverse drug reactions in neonatal intensive care units. Adverse Drug React Acute Poisoning Rev (1990) 1.06
Unrecognised ventricular dysfunction in COPD. Eur Respir J (2011) 1.06
A comprehensive assessment of the avoidability of long-term complications of diabetes. A case-control study. SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration. Diabetes Care (1996) 1.05
A pilot study of high-dose domperidone as an antiemetic in patients treated with cisplatin. Eur J Cancer Clin Oncol (1985) 1.05
Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant (1996) 1.05
Breast self-examination practice and its impact on breast cancer diagnosis in Alexandria, Egypt. East Mediterr Health J (2000) 1.04
Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer (1986) 1.03
Passive smoking and the risk of acute myocardial infarction GISSI-EFRIM investigations. Lancet (1993) 1.03
Profile of secondary prophylaxis among children with rheumatic heart disease in Alexandria, Egypt. East Mediterr Health J (2001) 1.02
Patterns of practice for acute myocardial infarction in a population from ten countries. Eur J Clin Pharmacol (1999) 1.02
Drug utilisation review and pharmacoeconomics: interaction after parallel development? Pharmacoeconomics (1993) 1.00
Cigarette smoking and the risk of cervical neoplasia. Am J Epidemiol (1986) 1.00
Control of hypertension in Italy: results of the "Study on Antihypertensive Treatment in General Practice (STAP)". Physicians Taking Part in STAP. G Ital Cardiol (1998) 0.99
CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res Bull (2008) 0.99
Warning signs in subarachnoid hemorrhage: a cooperative study. Acta Neurol Scand (1991) 0.98
The adequacy of diabetic care for children in a developing country. Diabetes Res Clin Pract (2001) 0.97
Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol (1984) 0.97
Prognosis of epilepsy in newly referred patients: a multicenter prospective study. Collaborative Group for the Study of Epilepsy. Epilepsia (1988) 0.97
Social factors, diet and breast cancer in a northern Italian population. Br J Cancer (1984) 0.96
Feasibility, limits and problems of clinical studies in Intensive Care Unit. Minerva Anestesiol (2007) 0.96
Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics (1998) 0.95
Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart (2003) 0.95
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics (2001) 0.95
Misoprostol and illegal abortion in Fortaleza, Brazil. Lancet (1993) 0.95
Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy. Acta Psychiatr Scand (1987) 0.95
Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Collaborative Group on Drug Use in Pregnancy (CGDUP). Eur J Clin Pharmacol (1993) 0.95
[Knowledge and perception of cardiovascular risk factors in Africa South of the Sahara]. Arch Mal Coeur Vaiss (2002) 0.94
Access to rehabilitation facilities in an unselected hospital population affected by acute stroke. Ital J Neurol Sci (1997) 0.93
Coffee consumption and the risk of breast cancer. Surgery (1986) 0.93
Patients' assessment of quality of care: a survey of a group of breast cancer patients in Italy. Tumori (1985) 0.92
Epidemiological problems with TCDD (a critical view). Drug Metab Rev (1982) 0.92
Impact of early access to a palliative/supportive care intervention on pain management in patients with cancer. Ann Oncol (2012) 0.91
A gas chromatographic method for the determination of amantadine in human plasma. J Chromatogr (1972) 0.91
Alcohol consumption and the risk of breast cancer in women. J Natl Cancer Inst (1985) 0.91
Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol (2001) 0.91
Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. Neurol Sci (2007) 0.91
A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. J Am Coll Cardiol (1994) 0.91